PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations.
about
The novel estrogen-induced gene EIG121 regulates autophagy and promotes cell survival under stressMutant p53 Drives Cancer by Subverting Multiple Tumor Suppression PathwaysTherapeutic targeting of cancers with loss of PTEN function.Personalized characterization of diseases using sample-specific networksMultiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastomaA novel PTEN/mutant p53/c-Myc/Bcl-XL axis mediates context-dependent oncogenic effects of PTEN with implications for cancer prognosis and therapyCooperation between c-Met and focal adhesion kinase family members in medulloblastoma and implications for therapy.An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth.microRNA-34a is tumor suppressive in brain tumors and glioma stem cells.An extensive invasive intracranial human glioblastoma xenograft model: role of high level matrix metalloproteinase 9.MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes.Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasionInteractions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapySlit2 inhibits glioma cell invasion in the brain by suppression of Cdc42 activity.Mutant p53 gain-of-function in cancer.Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.PTEN augments SPARC suppression of proliferation and inhibits SPARC-induced migration by suppressing SHC-RAF-ERK and AKT signaling.Evolutionary pathways in BRCA1-associated breast tumors.PTEN and p53 cross-regulation induced by soy isoflavone genistein promotes mammary epithelial cell cycle arrest and lobuloalveolar differentiationClinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma.Safe and targeted anticancer therapy for ovarian cancer using a novel class of curcumin analogsATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiationApplications of emerging molecular technologies in glioblastoma multiformeTargeting prostate cancer based on signal transduction and cell cycle pathways.Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia.PTEN-mediated ERK1/2 inhibition and paradoxical cellular proliferation following Pnck overexpression.Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme.TP53 mutants in the tower of babel of cancer progression.PI3K/Akt-mediated regulation of p53 in cancer.Trp53 Mutants Drive Neuroendocrine Lung Cancer through Loss-of-Function Mechanisms with Gain-of-Function Effects on Chemotherapy Response.Pnck overexpression in HER-2 gene-amplified breast cancer causes Trastuzumab resistance through a paradoxical PTEN-mediated process.Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53.Cell surface area and membrane folding in glioblastoma cell lines differing in PTEN and p53 status.HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer.Dual-specificity phosphatase DUSP6 has tumor-promoting properties in human glioblastomas.Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma.PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma.PTEN tumor suppressor plays less prognostic role than P53 tumor suppressor in diffuse large B-cell lymphoma.Potential therapeutic targets of TP53 gene in the context of its classically canonical functions and its latest non-canonical functions in human cancer.The p53 Pathway in Glioblastoma
P2860
Q24306770-86F1CC1C-BF25-4894-A0D8-65C7B309EF21Q26767396-37BA6841-7D7A-430D-86BD-2E3B24CBB5C0Q27852764-75D9AF78-941A-4C42-99A1-6DF3DBE72FFCQ28586781-B455A421-55CF-48DD-A8FA-A8E63C29E72EQ30405446-0145F0F1-1F84-43B3-994A-C23C68A51FB3Q30417988-95DB5BEB-4CEB-48A9-B205-4504EF075747Q30422676-84F338BA-9A95-4F7D-9899-FA071AC6D783Q30428363-43832642-3BB1-47FE-BD06-DB2D551D00A8Q30428366-803889BA-1E3B-4904-AF5D-756BF1357F7FQ30432036-74423DC7-2413-4E1C-9617-66347250BD7FQ30434616-45A86C45-3200-49B0-84B4-99576364E4F9Q30434675-9E6DF939-D2C0-4028-AE30-C67E9477E92EQ30437740-410EDC74-FEB0-4E4D-A016-7FF7687518E2Q33574529-22FBC703-A09D-44D6-A6A2-EA2D0A956F3CQ33687048-AC6CCA48-EFA0-426A-8CE5-77406B4B5ECEQ34103978-40321958-A468-4A56-AF8A-8B24D6BE162DQ34133079-059A4662-A399-4383-BA17-938D0F64349EQ34277174-04A610D8-5586-47E7-AF23-5520E22DDAB5Q34514602-A59932C1-73AC-4450-BC25-A42403554505Q34965421-54BD8F9C-C587-4BA3-8BD3-9733C7FD813FQ36880907-7D67D8FB-CC11-427C-B617-DEB02B78E1E3Q36941509-622674A2-2875-471A-A7FE-E88249F65A06Q36965370-E96C24E2-14D8-49F0-872E-94BE8A002194Q36995054-F76DB911-6947-469E-81F1-C92A6C2CD052Q37158722-E0DA515E-2DDE-4205-94D8-3F117B06CCE3Q37698905-9074C815-B62C-46E0-8DFC-395D5A9866A4Q38112074-9D673C4E-5ED8-4437-B48D-40F6D5B5BD33Q38180665-51560EDD-B385-4EFA-BB33-C5AD18EBD7ACQ38238609-34E1FFD8-C19F-4E55-A97A-055B63151034Q38605143-1B8FAAAD-8A7F-4D46-8675-0230ED170864Q38899532-096EA089-9B1D-4376-9F17-B9E013337C41Q39005896-6B699950-83D1-4D03-8949-80CC6421DC3BQ39027066-A22F9E68-E302-4489-AFED-0BAACA3854C0Q39307665-D0215621-34DE-4F4B-92E4-A2E4393E0B3AQ39557390-FF293201-6C2F-435D-A5ED-93BA5F4725ACQ39740608-6CEA5009-5F8D-4D50-9CF5-82AD7D2C7395Q39844741-68C501E9-C85B-4682-A7C7-B8AE9AB4D448Q42921293-B26B5E7B-6F70-4E50-A941-3884E0BBEC7DQ52584348-629F79BD-320B-45D6-A46F-E4229B9EC947Q57162865-BD0DC5B0-1505-4040-843C-9F050C8520B4
P2860
PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations.
@ast
PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations.
@en
type
label
PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations.
@ast
PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations.
@en
prefLabel
PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations.
@ast
PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations.
@en
P2093
P2860
P1433
P1476
PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations.
@en
P2093
Bachchu Lal
David Schiff
Elizabeth Johnson
Fadila Guessous
Isa Hussaini
John Laterra
Lauren Fuller
Manish Kumar
Opeyemi Ibidapo
Roger Abounader
P2860
P304
P356
10.1158/0008-5472.CAN-07-1963
P407
P577
2008-03-01T00:00:00Z